Moderna, Inc. (MRNA)
Moderna Secures $590M Funding From U.S. Government for Bird Flu Jab
MRNA intends to use the funds to support the development of its mRNA-based bird flu shot and expand clinical studies for additional subtypes of pandemic influenza.
Despite Setbacks, Moderna Sees Opportunity In Avian Flu, Merck Partnership
Moderna's recent stumbles make the company an acquisition target. Merck desperately needs Moderna's mRNA-based Personal Cancer Vaccines ("PCVs") to extend KEYTRUDA's patent protection beyond 2028. Merck stands to lose $62 billion over four years following the loss of exclusivity on KEYTRUDA, making Moderna's $13 billion market cap a bargain.
Is Moderna Stock a Buy?
Share prices of Moderna (MRNA 0.89%) plummeted 58% in 2024, ranking among the worst performers in the S&P 500 index. The biotech, renowned for its pioneering development of vaccines based on messenger RNA (mRNA), has struggled to manage weak sales of COVID-19 vaccine and sluggish market adoption of its new shot for respiratory syncytial virus (RSV).
Moderna is a 'trade' on Bird Flu vaccine pop, says Mizuho's Jared Holz
Jared Holz, Mizuho Healthcare Sector strategist, joins 'Closing Bell Overtime' to talk Moderna and Novo Nordisk.
Moderna Gets $590 Million of Federal Funding For Influenza Vaccines
The package will provide additional support for late-stage development and licensure of pre-pandemic mRNA-based vaccines, the company said
US awards Moderna $590 million for bird flu vaccine development
The U.S. government has awarded Moderna $590 million to advance the late-stage development of its mRNA bird flu vaccine, as the country doubles down on efforts to tackle increasing infections in humans.
How to Play Moderna Stock After the Recent Sales Guidance Cut
Given the uncertainty regarding its top-line growth, we would advise short-term investors to steer clear of MRNA stock.
The Zacks Analyst Blog Moderna, Regeneron, Intellia Sage and GSK
Moderna, Regeneron, Intellia Sage and GSK are included in this Analyst Blog.
Moderna Dropped by 20% This Week -- Is It a Smart Buy Right Now?
Although the stock market was having a generally strong week, that isn't the case for vaccine technology company Moderna (MRNA -2.72%). The company, which was a leader in developing one of the initial COVID-19 vaccines, has plunged by 20% for the week as of mid-day Thursday.
Is Moderna a Bad-News Buy for 2025?
Moderna (MRNA 0.90%) was one of the hottest companies of early pandemic times, delivering a coronavirus vaccine to market in record time and quickly generating blockbuster revenue from it. This helped the stock to skyrocket, reaching a high of more than $480 at its peak in 2021.
Down 79%, Is Moderna Stock a Bad-News Buy on the Dip?
Moderna (MRNA 0.90%) shareholders have been having a rough time lately. The biotech stock rocketed higher last spring, but the gains didn't last long.
Is Moderna Stock a No-Brainer Buy on the Sell-Off?
A bad seven-month stretch just got worse for Moderna (MRNA -1.96%). The messenger RNA (mRNA) pioneer provided a business and pipeline update at the J.P.
